This interview is part of our new AI in Healthcare series, where we interview the world's top thought leaders on the front lines of the intersections between AI and healthcare.
In this interview, we speak with Haza Newman, co-founder and CEO of Geras Solutions, to understand how his company is using AI to transform healthcare, and what the future of the industry holds.
1. What’s the story behind Geras Solutions? Why and how did you begin?
HN: Geras Solutions believes that paper-pen-based cognitive assessments are subjective, slow and out of date. This inspired us to develop an AI-based medical device that objectively measures cognition via thousands of digital data points, simplifies follow-up support for patients and professionals and guarantees access to validated risk reduction methods.
The company started as a project under Swedish Care International, an internationally active organization that develops, packages and exports Swedish elderly and dementia care.
2. Please describe your use case and how Geras Solutions uses AI:
HN: We use AI to simplify and streamline testing that can often be time-consuming while processing and organizing that data in such a way that helps provide a clinically validated and accurate assessment. Other options are providing access to support that may not be quickly received otherwise, and knowledge on how to lower dementia risk.
3. Could you share a specific customer/user that benefits from what you offer? What has Geras Solutions done for them?
HN: By providing such a tool, all dementia stakeholders can benefit, whether they require an assessment, specialist follow-up support, or just need to learn about how to lower their dementia risk. It is never too early or too late to make interventions that can lower the risk of developing cognitive impairment.
4. What other AI use cases in healthcare are you excited about?
HN: I am excited about cameras in mobile devices and how precise they are becoming. We should be creating solutions that tap into devices everyone already has today, such as phones.
5. Where will your company be in 5 years?
HN: We will have developed, grown and achieved our goal of lowering the non-detection rate around the world by simplifying access to dementia support and care. Doing so will require adaptation and constantly merging new technology and research, and using computational analysis to improve support and impairment detection.